Please ensure Javascript is enabled for purposes of website accessibility

WHO: There Are 70 Coronavirus Vaccines Currently in Development

By Prosper Junior Bakiny - Apr 14, 2020 at 5:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

While three of them are already clinical trials, expect an extended wait before any of them could be available for the general public.

As the COVID-19 pandemic continues to wreak havoc across the globe, efforts to find a vaccine that can prevent the disease continue to ramp up. According to the World Health Organization (WHO), there are now roughly 70 potential vaccines for SARS-CoV-2, the coronavirus that causes COVID-19, in development. Three of those vaccines are already in clinical trials, among them, Moderna's (MRNA -2.18%) candidate.

The National Institutes of Health is currently leading a phase 1 clinical trial for Moderna's potential vaccine. The trial will involve 45 healthy adult volunteers, each of whom will receive two doses of the vaccine about a month apart.  This trial will test the safety of the vaccine, its immunogenicity -- which refers to its ability to trigger an immune response in the body -- and the amount that causes expected side effects. As an early-stage trial, however, it will not attempt to gauge the vaccine's efficacy. 

Face mask with COVID-19 written on it.

Image Source: Getty Images.

CanSino Biologics, a China-based company that focuses on vaccine development, currently has the candidate that is furthest advanced in the trial process. It recently started a phase 2 clinical trial for Ad5-nCoV, its investigational SARS-CoV-2 vaccine. This trial will involve 500 adults who will be divided into three groups. Members of the first group, comprised of 250 people, will receive what it describes as a "middle dose" of Ad5-nCoV, while those in the second group of 125 people will receive a "low dose." The 125 people in the third group will receive placebos. The trial will test the safety and immunogenicity of the vaccine.

Although the efforts of biotechnology companies to develop a vaccine that could prevent COVID-19 are commendable, it isn't time to celebrate just yet. Despite the large number of vaccine candidates currently in development, it will likely take a year or more for researchers to determine if any of them are effective enough to be given to the public at large. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$142.19 (-2.18%) $-3.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.